JAK inhibitors tested in clinical trials in MF
| Agent . | Other targets . | Phase . |
|---|---|---|
| Ruxolitinib | JAK1 | 3 (approved) |
| Fedratinib (SAR302503) | FLT3, RET | 3 (withdrawn) |
| Pacritinib (SB1518) | FLT3 | 3 |
| Momelotinib (CYT387) | JAK1, JNK1, TYK2, CDK2, RICJ2 | 3 |
| Lestaurtinib (CEP-701) | FLT3, TRKA | 2 (withdrawn) |
| AZD1480 | JAK1, JAK3, FLT4, FGFR1, TRKA | 2 |
| Gandotinib (LY2784544) | — | 1 (withdrawn) |
| XL019 | — | 1 (withdrawn) |
| NS-018 | SRC, FLT3, ABL | 1/2 |
| BMS-911543 | — | 1/2 (withdrawn) |
| Agent . | Other targets . | Phase . |
|---|---|---|
| Ruxolitinib | JAK1 | 3 (approved) |
| Fedratinib (SAR302503) | FLT3, RET | 3 (withdrawn) |
| Pacritinib (SB1518) | FLT3 | 3 |
| Momelotinib (CYT387) | JAK1, JNK1, TYK2, CDK2, RICJ2 | 3 |
| Lestaurtinib (CEP-701) | FLT3, TRKA | 2 (withdrawn) |
| AZD1480 | JAK1, JAK3, FLT4, FGFR1, TRKA | 2 |
| Gandotinib (LY2784544) | — | 1 (withdrawn) |
| XL019 | — | 1 (withdrawn) |
| NS-018 | SRC, FLT3, ABL | 1/2 |
| BMS-911543 | — | 1/2 (withdrawn) |